Monoclonal Antibody to Inhibit PCSK9 for Inflammation and Metabolic Disorders is under clinical development by Ligand Pharmaceuticals and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Monoclonal Antibody to Inhibit PCSK9 for Inflammation and Metabolic Disorders’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Monoclonal Antibody to Inhibit PCSK9 for Inflammation and Metabolic Disorders overview

Monoclonal antibody is under development for the treatment of inflammation and metabolic disorders. It acts by targeting proprotein convertase subtilisin/kexin Type 9. The drug candidate is being developed based on OmniAb technology.

Ligand Pharmaceuticals overview

Ligand Pharmaceuticals (Ligand) develops and acquires technologies that help biopharmaceutical companies in the discovery and development of medicines. Its major research technologies include formulation science, structure-based drug design, antibody discovery technologies and liver targeted pro-drug technologies, which assist pharmaceutical companies in securing approval for prescription drugs. Its technologies and research capabilities contributed to the development of a diversified portfolio of biotechnology and pharmaceutical products for the inflammatory, respiratory central nervous system, oncology, ophthalmology, hematology, musculoskeletal disorder, and osteoporosis, among others. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

For a complete picture of Monoclonal Antibody to Inhibit PCSK9 for Inflammation and Metabolic Disorders’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.